NIH R01 · 2025
Mechanisms of genetic and non-genetic resistance to KRAS inhibition
PROJECT SUMMARY KRAS is the most frequently mutated oncogene in lung adenocarcinoma (LUAD) and colorectal cancer (CRC). In the US alone, cancers carrying KRAS mutations account for almost 100,000 deaths per year. New mutant- selective and pan-KRAS inhibitors have recently emerged as a potent and effective strategy to block KRAS- mediated oncogenic signaling, however early clinical signs suggests that drug resistance is not only possible, but a common outcome to KRAS-targeted treatment. Defining the mechanism/s underlying acquired resistance to KRAS targeted therapies will drive more effective treatment stratification for patients and guide the development of combination or second-line…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.